Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2011-06-28
2011-06-28
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C514S056000, C505S844000
Reexamination Certificate
active
07968082
ABSTRACT:
Methods for analyzing mixtures of polysaccharides, for example heparin such as enoxaparin are described. In some instances, the mixtures are analyzed using 1D NMR and/or 2D NMR.
REFERENCES:
patent: 4692435 (1987-09-01), Lormeau
patent: 5389618 (1995-02-01), Debrie
patent: 6617316 (2003-09-01), Mourier et al.
patent: RE38743 (2005-06-01), Debrie
patent: 7083937 (2006-08-01), Sasisekharan et al.
patent: 7585642 (2009-09-01), Sasisekharan et al.
patent: 2002/0169143 (2002-11-01), Sasisekharan et al.
patent: 2003/0203385 (2003-10-01), Venkataraman et al.
patent: 2004/0265943 (2004-12-01), Viskov et al.
patent: 2005/0119477 (2005-06-01), Mourier et al.
patent: 2005/0186679 (2005-08-01), Viskov et al.
patent: 2005/0215519 (2005-09-01), Viskov et al.
patent: 2005/0288252 (2005-12-01), Nurcombe et al.
patent: 2006/0024664 (2006-02-01), Sasisekharan et al.
patent: 2007/0065921 (2007-03-01), Sasisekharan et al.
patent: 2007/0098708 (2007-05-01), Myette
patent: 2007/0161073 (2007-07-01), Sasisekharan et al.
patent: 2007/0287683 (2007-12-01), Shriver et al.
patent: 2008/0009069 (2008-01-01), Mourier et al.
patent: 1580197 (2005-09-01), None
patent: 1582531 (2005-10-01), None
patent: 1586588 (2005-10-01), None
patent: WO9003791 (1990-04-01), None
patent: WO 01/29055 (2001-04-01), None
patent: WO 03/078960 (2003-09-01), None
patent: WO 2004/027087 (2004-04-01), None
patent: WO 2005/009040 (2005-01-01), None
patent: WO 2005/080438 (2005-09-01), None
patent: WO 2005/090411 (2005-09-01), None
Campbell, S.A. (2004) Filed by Amphastar Pharmaceuticals in Response to Citizen Petition Docket No. 03P-0064/CP1 filed with the United States Food and Drug Administration. Response filed on May 13, 2004, Entered inito FDA docket system on Jun. 8, 2004.
Ansel, H.C., Allen, Jr., L.V., Popovich, N.G. (1999) Pharmaceutical Dosage Forms and Drug Delivery Systems. Published by Lippincott Williams & Wilkins, p. 23-27 and 54-59.
Yates, E.A., Santini, F., Guerrini, M., Naggi, A., Torri, G., Casu, B. (1996) 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydrate Research, vol. 294, p. 15-27.
Guerrini, M., Naggi, Guglieri, S., Santarsiero, R., Torri,G. (2005) Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Analytical Biochemistry, vol. 337, p. 35-47.
Piani, S., Casu, B., Marchi, E.G., Torri, G., Ungarelli, F. (1993) Alkali-Induced Optical Rotation Changes in Heparins and Heparan Sulfates, and Their Relation to Iduronic Acid-Containing Sequences. Journal of Carbohydrate Chemistry, vol. 12, No. 4&5, p. 507-521.
Hricovini, M., Guerrini, M., Torri, G., Piani, S., Ungarelli. F. (1995) Conformational analysis of heparin epoxide in aqueous solution. An NMR relaxation study. Carbohydrate Research, vol. 277, p. 11-23.
Perlin, A.S., Casu, B. (1982) Spectroscopic Methods in The Polysaccharides. Edited by G.O. Aspinall, published by Academic Press, vol. 1, p. 133-193.
Guerrini, M., Bisio, A., Torri, G. (2001) Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations. Seminars in Thrombosis and Hemostasis, vol. 27, No. 5, p. 473-482.
Ampofo, S. et al., “Disaccharide Compositional Analysis of Heparin and Heparan Sulfate Using Capillary Zone Electrophoresis,”Analytical Biochem., 199:249-255 (1991).
Da Col, R. et al., “Characterization of the Chemical Structure of Sulphated Glycosaminoglycans After Enzymatic Digestion. Application for Liquid Chromatography-Mass Spectrometry with an Atmospheric Pressure Interface,”J. of Chromatography, 647:289-300 (1993).
Desai, U. et al., “Oligosaccharide Composition of Heparin and Low-molecular-weight Heparins by Capillary Electrophoresis,”Analytical Biochem., 213:120-127 (1993).
Ernst, S. et al., “Direct Evidence for Predominantly Exolytic Processive Mechanism for Depolymerization of Heparin-like Glycosaminoglycans by Heparinase I,”PNAS, 95:4182-4187 (1998).
Guo, Y. et al., “The Disaccharide of Heparins and Heparan Sulfates,”Analytical Biochem., 176:96-104 (1989).
Imanari, T. et al., “High-performance Liquid Chromatographic Analysis of Glycosaminoglycan-derived Oligosaccharides,”J. of Chromatography A, 720:275-293 (1996).
Karamanos, N. et al., “Ion-pair High-performance Liquid Chromatography for Determining Disaccharide Composition in Heparin and Heparan Sulphate,”J. of Chromatography A, 765:169-179 (1997).
Kariya, Y. et al., “Disaccharide Analysis of Heparin and Heparan Sulfate Using Deaminative Cleavage with Nitrous Acid and Subsequent Labeling with Paranitrophenyl Hydrazine,”J. Biochem. (Tokyo), 123(2):240-6 (1998) Abstract Only.
Kinoshita, A. et al., “Microanalysis of Glycosaminoglycan-derived Oligosaccharides Labeled with a Fluorophore 2-aminobenzamide by High-performance Liquid Chromatography: Application to Disaccharide Composition Analysis of Exosequencing of Oligosaccharides,”Analytical Biochem., 269:367-378 (1999).
Lamari, F. et al., “Analysis of Glycosaminoglycan-derived Disaccharides in Biologic Samples by Capillary Electrophoresis and Protocol for Sequencing Glycosaminoglycans,”Biomedical Chromatography, 16:95-102 (2002).
Lee, G. et al., “Separation of Reduced Disaccharides Derived from Glycosaminoglycans by High-performance Liquid Chromatography,”J. of Chromatography, 212:65-73 (1981).
Lindhart, R. et al., “Mapping and Quantification of the Major Oligosaccharide Components of Heparin,”Biochem. Journal, 254:781-787 (1988).
Linhardt, R. et al., “Oligosaccharide Mapping of Low Molecular Weight Heparins: Structure and Activity Differences,”J. of Medicinal Chem., 33(6):1639-1645 (1990).
Lindhardt, R. et al., “New Methodologies in Heparin Structure Analysis and the Generation of LMW Heparins,”Heparin and Related Polysaccharides, 37-47, ed. D.A. Lane et al., Plenum Press, New York (1992).
Merchant, K. et al., “Structure of Heparin-derived Tetrasaccharides,” Biochem. Journal, 229:369-377 (1985).
Militsopoulou, M. et al., “Determination of 12 Heparin- and Heparan Sulfate-derived Disaccharides as 2-aminoacridone Derivatives by Capillary Zone Electrophoresis Using Ultraviolet and Laser-induced Flourescence Detection,”Electrophoresis, 23:1104-1109 (2002).
Park, Y. et al., “Purification and Characterization of Heparin Sulphate Proteoglycan from Bovine Brain,” Biochem. Journal, 344:723-730 (1999).
Pervin, A. et al., “Separation of Glycosaminoglycan-derived Oligosaccharides by Capillary Electrophoresis Using Reverse Polarity,”Analytical Biochem., 221:182-188 (1994).
Rhomberg, A. et al., “Mass Spectrometric and Capillary Electrophoretic Investigation of the Enzymatic Degradation of Heparin-like Glycosaminoglycans,” PNAS, 95:4167-4181 (1998).
Rice, K. et al., “High-performance Liquid Chromatographic Separation of Heparin-derived Oligosaccharides,”Analytical Biochem., 150(2):325-31 (1985) Abstract Only.
Ruiz-Calero, V. et al., “Pressure-assisted Capillary Electrophoresis-electrospray Ion Trap Mass Spectrometry for the Analysis of Heparin Depolymerised Disaccharides,”J. of Chromatography A, 914:277-291 (2001).
Ruiz-Calero, V. et al., “Use of Reversed Polarity and a Pressure Gradient in the Analysis of Disaccharide Composition of Heparin by Capillary Electrophoresis,”J. of Chromatography A, 828:497-508 (1998).
Saad, O. et al., “Compositional Analysis and Quantification of Heparin and Heparan Sulfate by Electrospray Ionization Ion Trap Mass Spectrometry,”Anal. Chem., 75:2985-2995 (2003).
Scapol, L. et al., “Capillary Electrophoresis of Heparin and Dermatan Sulfate Unsaturated Disaccharides with Triethylamine and Acetonitrile as Elecrolyte Additives,”J. of Chromatography A., 735:367-374, (1996).
Thanawiroon, C. et al., “Separation of a Complex Mixture of Hep
Beccati Daniela
Capila Ishan
Lansing Jonathan
Shriver Zachary
Goon Scarlett
Jiang Shaojia Anna
Lando & Anastasi LLP
Momenta Pharmaceuticals, Inc.
LandOfFree
Evaluating mixtures of low molecular weight heparins by NMR does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Evaluating mixtures of low molecular weight heparins by NMR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Evaluating mixtures of low molecular weight heparins by NMR will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638157